MUMBAI (Reuters) - Drug firm Suven Life Sciences Ltd said on Tuesday it secured its first product patents for three new drug molecules being developed to treat neuro degenerative disorders.The patents granted by the Indian Patent Office are valid until 2022, Suven said in a statement.
